Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 24;79(20):2037-2057.
doi: 10.1016/j.jacc.2022.03.349.

Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review

Affiliations
Free article
Review

Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review

Evin Yucel et al. J Am Coll Cardiol. .
Free article

Abstract

The incidence of injection drug use-associated infective endocarditis has been increasing rapidly over the last decade. Patients with drug use-associated infective endocarditis present an increasingly common clinical challenge with poor long-term outcomes and high reinfection and readmission rates. Their care raises issues unique to this population, including antibiotic selection and administration, indications for and ethical issues surrounding surgical intervention, and importantly management of the underlying substance use disorder to minimize the risk of reinfection. Successful treatment of these patients requires a broad understanding of these concerns. A multidisciplinary, collaborative approach providing a holistic approach to treating both the acute infection along with effectively addressing substance use disorder is needed to improve short-term and longer-term outcomes.

Keywords: cardiac surgery; infective endocarditis; medications for opioid use disorder; opioid use disorder; people who inject drugs; percutaneous mechanical aspiration; substance use disorder; tricuspid valve endocarditis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Bearnot is supported by the National Institutes of Health/National Institute on Drug Abuse under grant K12DA043490. Dr Rosenfield has served as a consultant and/or Scientific Advisory Board member for Althea Medical, Angiodynamics, Boston Scientific, Contego, InspireMD, Magneto, Mayo Clinic, Neptune Medical, Phillips, Summa Therapeutics, Surmodics, Thrombolex, Terumo, and Truvic; holds equity in Accolade, Access Vascular, Aerami, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMD, JanaCare, Magneto, Orchestra, PQ Bypass, Prosomnus, Shockwave, Summa Therapeutics, Thrombolex, Truvic, and Valcare; and is a Board Member for National PERT Consortium. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Publication types

MeSH terms

Substances

LinkOut - more resources